3-piperidyl-4-oxoquinazoline derivatives and pharmaceutical compositions comprising the same
申请人:Japan Tobacco, Inc.
公开号:US06235730B1
公开(公告)日:2001-05-22
3-piperidyl-4-oxoquinazoline derivatives are provided, which is represented by the formula (I):
wherein R represents an amino group or a cyclic amino group such as dibenzoazepine, each of which is substituted with a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, or the like, n is an integer of 1 to 3, R3 and R4 independently represents a hydrogen atom, a lower alkyl group, or the like, or a pharmaceutically acceptable salt thereof. Compounds (I) of the present invention have excellent MTP-inhibitory activity. Thus, these compounds not only inhibit formation of LDL that is a cause of arteriosclerotic diseases but also regulate TG, cholesterol, and lipoproteins such as LDL in the blood and regulate cellular lipids through regulation of MTP activity. They can also be used as a new type of preventive or therapeutic agents for hyperlipemia or arteriosclerotic diseases. Furthermore, they can be used as therapeutic or preventive agents for pancreatitis, obesity, hypercholesterolemia, and hypertriglyceridemia.
提供了3-哌啶基-4-酮喹唑啉衍生物,其化学式表示为(I):其中R代表氨基或环氨基,如二苯并蒽,每个都被取代或未取代的芳基、取代或未取代的杂环芳基等所取代,n为1至3的整数,R3和R4独立地表示氢原子、较低的烷基或类似物,或其药学上可接受的盐。本发明的化合物(I)具有出色的MTP抑制活性。因此,这些化合物不仅抑制了是动脉粥样硬化疾病原因之一的LDL的形成,而且通过调节MTP活性,还可以调节血液中的甘油三酯、胆固醇和LDL等脂蛋白,并通过调节细胞脂质来调节细胞脂质。它们还可以作为新型的高脂血症或动脉粥样硬化疾病的预防或治疗药物。此外,它们还可以作为胰腺炎、肥胖症、高胆固醇血症和高甘油三酯血症的治疗或预防药物。